Medigene AG Reports Half-Year 2024 Financial Results and Provides Corporate Update Significant corporate and scientific progress in the first half of 2024Advancement of lead program MDG1015 with IND filing on track for 3Q 2024 and CTA filing for 4Q 2024New additions to...

Medigene AG Reports Second Quarter and Six Months 2023 Financial Results and Provides Corporate Update Pipeline expansion into neoantigens with multiple KRAS mutations as the first targets Acquired exclusive, worldwide rights to a CD40L-CD28 costimulatory switch protein Data from MDG1015 and multiple...

Medigene AG to report Second Quarter and Six Months 2023 Financial Results and Corporate Update on August 17, 2023 Planegg/Martinsried, August 10, 2023.  Medigene AG (Medigene or the “Company”, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and development of T cell...